BANCAP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BANCAP (BANCAP).
BANCAP (hydrocodone/acetaminophen) exerts its analgesic effects through the central nervous system. Hydrocodone is an opioid agonist that binds to mu-opioid receptors, inhibiting pain transmission. Acetaminophen inhibits cyclooxygenase enzymes centrally and peripherally, reducing prostaglandin synthesis and providing antipyretic and analgesic effects.
| Metabolism | Hydrocodone: CYP3A4 and CYP2D6; Acetaminophen: primarily conjugated via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation, with minor CYP2E1-mediated oxidation. |
| Excretion | Primarily renal (90-100% as metabolites, mainly glucuronide conjugates and sulfate; <5% unchanged). Biliary/fecal elimination is minimal (<5%). |
| Half-life | Terminal elimination half-life: 1.5-3 hours, prolonged in hepatic impairment (up to 6-8 hours) or severe liver disease. Overdose: half-life increases >4 hours due to saturation of metabolic pathways. |
| Protein binding | 10-25% bound to albumin (weak binding; negligible clinical significance). |
| Volume of Distribution | 0.9-1.0 L/kg in adults; higher in children (1.0-1.5 L/kg). Indicates wide distribution into body fluids and tissues (CNS, placenta, milk). |
| Bioavailability | Oral: 60-90% (first-pass metabolism reduces bioavailability; tablet/capsule: ~80% typically). Rectal: ~70-80% (variable due to absorption differences). IV: 100%. |
| Onset of Action | Oral: 30-60 minutes (analgesic effect). Rectal: 60-90 minutes. IV: 5-10 minutes (analgesic effect). |
| Duration of Action | Oral: 4-6 hours (analgesic); Rectal: 4-6 hours; IV: 4-6 hours. Extended-release formulations: 8-12 hours (consult specific product). Clinical note: Duration shorter in children and in febrile states. |
1-2 tablets (325-650 mg acetaminophen and 30-60 mg caffeine) orally every 4-6 hours as needed; maximum 8 tablets per day.
| Dosage form | CAPSULE |
| Renal impairment | GFR 10-50 mL/min: administer every 6 hours. GFR <10 mL/min: administer every 8 hours. Avoid in severe renal impairment (anuria). |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity risk. |
| Pediatric use | Not recommended for children under 12 years. For ages 12-18: same as adult dosing but limit to 5 days of use. |
| Geriatric use | No specific dosage adjustment required, but caution due to potential caffeine sensitivity and increased risk of acetaminophen hepatotoxicity; limit to 4 tablets per day and monitor liver function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BANCAP (BANCAP).
| Breastfeeding | Acetaminophen: M/P ratio ~0.91-1.42, excreted in milk in small amounts, considered compatible. Butalbital: M/P ratio ~0.49, excreted in milk; significant sedation risk in infant, especially with chronic use; avoid or monitor for drowsiness, poor feeding. Caffeine: M/P ratio ~0.72-0.84, moderate excretion; may cause irritability in infant. Overall: caution, avoid prolonged use. |
| Teratogenic Risk | BANCAP (acetaminophen 500 mg, butalbital 50 mg, caffeine 40 mg) has limited data. Acetaminophen is generally considered low risk, but chronic high doses may be associated with adverse outcomes. Butalbital is a barbiturate; first trimester use may be associated with neural tube defects; chronic use in late pregnancy can cause neonatal withdrawal syndrome and neonatal hemorrhage due to vitamin K deficiency. Caffeine crosses placenta; high intake linked to low birth weight. Overall risk profile: first trimester – possible minor malformations with butalbital; second/third trimester – risk of dependence, withdrawal, hemorrhage. |
■ FDA Black Box Warning
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; interaction with alcohol (hepatotoxicity).
| Serious Effects |
Hypersensitivity to hydrocodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use with MAOIs or within 14 days.
| Precautions | Respiratory depression; opioid-induced hyperalgesia; adrenal insufficiency; hypotension; seizures; hepatotoxicity (acetaminophen); severe hypotension; risks of use in patients with head injury; gastrointestinal effects; urinary retention; severe dermatologic reactions (Stevens-Johnson syndrome); interaction with MAOIs; abuse potential; neonatal opioid withdrawal syndrome. |
| Food/Dietary | Avoid excessive caffeine from coffee, tea, soda, or chocolate as it adds to the caffeine in Bancap, potentially causing nervousness, insomnia, or tachycardia. Alcohol should be avoided due to increased hepatotoxicity risk with acetaminophen. |
Loading safety data…
| Fetal Monitoring | Monitor maternal: liver function (acetaminophen toxicity risk with high doses), signs of butalbital dependence or withdrawal (sedation, dizziness). Monitor fetal: growth ultrasound if chronic use (risk of low birth weight), assess for neonatal withdrawal signs after delivery (hypertonia, seizures, poor feeding). Neonatal coagulation status if butalbital used near term (vitamin K deficiency). |
| Fertility Effects | Limited data. Chronic use of butalbital may disrupt menstrual cycles and ovulation via CNS depression. Acetaminophen and caffeine in standard doses unlikely to impair fertility significantly. High caffeine intake (>300 mg/day) has been associated with delayed conception. Animal studies with butalbital show reproductive toxicity at high doses. |
| Clinical Pearls | Bancap is a combination of butalbital, acetaminophen, and caffeine used for tension headaches. Due to butalbital, there is a risk of dependence and withdrawal with prolonged use. Acetaminophen hepatotoxicity can occur if patients exceed 4 g/day or have underlying liver disease. Caffeine can exacerbate anxiety or insomnia. Limit use to less than 2 days per week to avoid medication-overuse headache. |
| Patient Advice | Take exactly as prescribed; do not exceed recommended dose. · Avoid alcohol while taking this medication due to increased risk of liver damage. · Do not use more than 4 grams of acetaminophen in 24 hours from all sources. · May cause drowsiness; avoid driving or operating machinery until you know how you react. · Do not stop abruptly after prolonged use to avoid withdrawal symptoms. · Report any signs of liver injury: yellowing of skin/eyes, dark urine, abdominal pain. · Limit caffeine from other sources to avoid jitteriness or insomnia. |